Balyasny Asset Management
ASMB icon

Balyasny Asset Management’s Assembly Biosciences ASMB Stock Holding History

Balyasny Asset Management’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,917
Closed -$1.37M – 1650
2018
Q2 		$1.37M Buy
+2,917
New +$1.54M 0.01% 1051

Other funds holding ASMB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Balyasny Asset Management's ASMB Position: Q3 2018 in Review

Balyasny Asset Management sold out of Assembly Biosciences (ASMB) in Q3 2018, closing a stake of 2,917 shares — an estimated $1.37M sold.

Balyasny Asset Management first reported a position in ASMB in Q2 2018 and held it in 1 quarter. The position peaked at $1.37M in Q2 2018. 113 funds tracked by Wall St. Rank hold ASMB as of Q3 2018.

  • Balyasny Asset Management reported no remaining Assembly Biosciences position as of Q3 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 2,917 Assembly Biosciences shares in Q3 2018, an estimated $1.37M.
  • Balyasny Asset Management first reported a position in Assembly Biosciences in Q2 2018 and held it in 1 quarter.
  • Balyasny Asset Management's Assembly Biosciences position peaked at $1.37M in Q2 2018.
  • 113 funds tracked by Wall St. Rank held Assembly Biosciences as of Q3 2018.

Based on Balyasny Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.